Merck: to acquire Germany's Rigontec for 115 million euros.
(CercleFinance.com) - US drug giant Merck said on Wednesday that it will acquire Rigontec, a German firm that specialises in cancer immunotherapy and anti-tumor immunity, for 115 million euros in cash.
Subject to reaching certain clinical, development, regulatory and commercial milestones, Merck could make additional payments of up to 349 million euros, the company said.
Rigontec was founded in 2014 as a spin-out from the University of Bonn.
Rigontec's lead candidate, RGT100, is currently in Phase I development evaluating treatment in patients with different tumours.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
Subject to reaching certain clinical, development, regulatory and commercial milestones, Merck could make additional payments of up to 349 million euros, the company said.
Rigontec was founded in 2014 as a spin-out from the University of Bonn.
Rigontec's lead candidate, RGT100, is currently in Phase I development evaluating treatment in patients with different tumours.
Copyright (c) 2017 CercleFinance.com. All rights reserved.